Three publications confirm the effectiveness of the FR104, Effimune’s leading molecule
Effimune announced , the publication in leading scientific journals of three different studies confirming the efficacy of FR104 in new... View Article
Keosys : positive results from Phase 3 NETTER-1 Study
Keosys announces positive results from Phase 3 NETTER-1 Study centralized and assessed by its Innovative Cloud based Clinical Trial Imaging... View Article
€5.8 million to start a new era in vaccine purification
The DiViNe initiative, a joint European collaboration of renowned experts, convinced the European Commission. Its main concept is “positive“ vaccines... View Article
Recherche clinique : le CHU de Nantes et l’ICO reconnue par l’INCa
Avec l’obtention du label CLIP2 (Centres Labellisés INCa de Phase Précoce), le dynamisme de la recherche clinique du CHU de... View Article
DigitalforLife: Digital enterprises, meet health challenges
On May 28th, at the Ecole des Mines de Nantes, the fourth Digital & Health day took place. It was... View Article
Hemarina, 1er prix du Concours des Technologies Médicales Innovantes
L’entreprise Hemarina, accompagnée par ID2Santé et membre d’Atlanpole Biotherapies, est lauréate du Concours TMI 2015 organisé par l’Alliance pour le... View Article
AAA Signs Distribution Agreement for Lutathera in Japan with FUJIFILM RI Pharma, Co., LTD
Advanced Accelerator Applications S.A., an international specialist in Molecular Nuclear Medicine (MNM) and member of Atlanpole Biotherapies, announce s that... View Article
Press Release BIOMATLANTE obtains CE approval to market its OSTEOTWIN™ Affix Sheath
BIOMATLANTE (Vigneux de Bretagne ), a medical devices company specialized in bone regeneration and member of Atlanpole Biotherapies, today announced... View Article
Program IHU CESTI: StemHepTher, promising alternatives to liver transplantation
Many types of diseases, whether of genetic origin or not, present a severe dysfunction or generalized dysfunctions of the liver,... View Article